LCK is involved in cytoskeletal organisation and integrin signalling and has been shown to support compensatory EGFR signalling in cholangiocarcinoma43 Its predictive role has also been supported in clinical cohorts of lapatinib-treated breast cancer patients42, further validating the model’s performance. The gene discussed is LCK; the disease is breast carcinoma.